Cargando…
Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant
We developed a SARS-CoV-2 spike subunit vaccine formulation containing dual TLR ligand liposome adjuvant. The vaccine-induced robust systemic neutralizing antibodies and completely protected mice from a lethal challenge. Two immunizations protected against lung injury and cleared the virus from lung...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602664/ https://www.ncbi.nlm.nih.gov/pubmed/34795290 http://dx.doi.org/10.1038/s41541-021-00399-0 |